en · de · es · fr · pt
aod-9604-notes.peptides9000.com › Faq › Handling And Analytical Properties — Research Overview

Handling And Analytical Properties — Research Overview

By Editorial Desk · published 2026-07-29 · last reviewed 2026-08-01 · Faq

lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Handling And Analytical Properties

AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.

Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.

Background and Development History

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

Aod-9604 at a glance

PropertyValueNotes
AppearanceWhite to off-white powderLyophilized form; may appear as cake
Solubility classWater-solubleOften reconstituted in aqueous buffer
Typical storage temperature−20 °C or belowProtect from light and moisture
Typical analytical methodRP-HPLC and mass spectrometryUsed for purity and identity
Common synonymsAOD-9604; AOD9604; hGH fragment 176-191Research name and fragment description

Background and Molecular Identity

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Related pages on this site

Identity And Research Background

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

Supporting material

=== Sources === For the most part, vitamins are obtained from the diet, but some are acquired by other means: for example, microorganisms in the gut flora produce vitamin K and biotin; and one form of vitamin D is synthesized in skin cells when they are exposed to a certain wavelength of ultraviolet light present in sunlight. Humans can produce some vitamins from precursors they consume: for example, vitamin A is synthesized from beta carotene; and niacin is synthesized from the amino acid tryptophan. Vitamin C can be synthesized by some species but not by others. Vitamin B12 is the only vitamin or nutrient not available from plant sources. The Food Fortification Initiative lists countries which have mandatory fortification programs for vitamins folic acid, niacin, vitamin A and vitamins B1, B2 and B12.

Pyongan Province Non-traditional ingredients have been adopted in rural areas due to severe food shortages. Hamgyong Province: Due to its proximity to the ocean, people in this particular region use fresh fish and oysters to season their kimchi. Hwanghae Province: The taste of kimchi in Hwanghae Province is not bland but not extremely spicy. Most kimchi from this region have less color since red chili flakes are not used. The typical kimchi in Hwanghae Province is called hobakji (호박지). It is made with pumpkin (bundi). Gyeonggi Province Chungcheong Province: Instead of using fermented fish, people in the region rely on salt and fermentation to make savory kimchi. Chungcheong Province has the most varieties of kimchi. Gangwon Province, South Korea/Kangwon Province, North Korea: In Gangwon Province, kimchi is stored for longer periods. Unlike other coastal regions in Korea, kimchi in this area does not contain much salted fish. Jeolla Province: Salted yellow corvina and salted butterfish are used in this region to create different seasonings for kimchi. Gyeongsang Province: This region's cuisine is saltier and spicier. The most common seasoning components include myeolchijeot (멸치젓) which produces a briny and savory flavor. They also use oysters in their kimchi. Foreign countries: In some places of the world people sometimes make kimchi with western cabbage and many other alternative ingredients such as broccoli.

== Applications == The SDS-PAGE in combination with a protein stain is widely used in biochemistry for the quick and exact separation and subsequent analysis of proteins. It has comparatively low instrument and reagent costs and is an easy-to-use method. Because of its low scalability, it is mostly used for analytical purposes and less for preparative purposes, especially when larger amounts of a protein are to be isolated. Additionally, SDS-PAGE is used in combination with the western blot for the determination of the presence of a specific protein in a mixture of proteins - or for the analysis of post-translational modifications. Post-translational modifications of proteins can lead to a different relative mobility (i.e. a band shift) or to a change in the binding of a detection antibody used in the western blot (i.e. a band disappears or appears). In mass spectrometry of proteins, SDS-PAGE is a widely used method for sample preparation prior to spectrometry, mostly using in-gel digestion. In regards to determining the molecular mass of a protein, the SDS-PAGE is a bit more exact than an analytical ultracentrifugation, but less exact than a mass spectrometry or - ignoring post-translational modifications - a calculation of the protein molecular mass from the DNA sequence. In medical diagnostics, SDS-PAGE is used as part of the HIV test and to evaluate proteinuria. In the HIV test, HIV proteins are separated by SDS-PAGE and subsequently detected by Western Blot with HIV-specific antibodies of the patient, if they are present in his blood serum.

=== Books === Chromatographic Determination of Molecular Interactions (1994) ISBN 9780849344374 Physicochemical and Biomimetic Properties in Drug Discovery: Chromatographic Techniques for Lead Optimization (2014) ISBN 9781118152126 Separation Methods in Drug Synthesis and Purification (2020) ISBN 9780444640703

Sources: en.wikipedia.org

Notes from published material

== Orthogonal methods == Field-flow fractionation (FFF) can be considered as an alternative to GPC, especially when particles or high molar mass polymers cause clogging of the column, shear degradation is an issue or agglomeration takes place but cannot be made visible. FFF is separation in an open flow channel without having a static phase involved so no interactions occur. With one field-flow fractionation version, thermal field-flow fractionation, separation of polymers having the same size but different chemical compositions is possible.

Dr. Stone is an anime television series produced by TMS Entertainment based on the manga series of the same name written by Riichiro Inagaki and illustrated by Boichi. Set 3,700 years after a mysterious light turns every human on the planet into stone, genius boy Senku Ishigami emerges from his petrification into a "Stone World" and seeks to rebuild human civilization from the ground up. Dr. Stone's second season, titled Dr. Stone: Stone Wars, aired from January 14 to March 25, 2021. The season premiered on Tokyo MX and KBS in a dual simulcast, with other networks following at later timeslots. It focuses on the story of the "Stone Wars" arc from the manga, in which Senku and the Ishigami villagers of the Kingdom of Science go to war with Tsukusa's Kingdom of Strength. The season is streamed by Crunchyroll worldwide outside of Asia, while then-separate company Funimation produced a simuldub. The season ran for 11 episodes. A sequel was announced after second season finale. The English dub for Stone Wars aired on Adult Swim's Toonami programming block from May 16 to July 25, 2021. The opening theme song is "Rakuen" (楽園; lit. 'Paradise') performed by Fujifabric, while the ending theme song is "Koe?" (声?; lit. 'Voice?') performed by Hatena.

=== Infertility === It can be difficult to become pregnant with PMOS due to irregular ovulation. The first management step is to improve the general health of the mother, such as through lifestyle interventions. GLP-1 agonist for weight loss can be used, but should be stopped at least 2 months before conception. As of 2025, there is not enough data to know if they are safe in pregnancy. Pregnancy in PMOS is more risky than normal, and treatment is focused on getting a single pregnancy, rather than, for instance, twins (multiple pregnancy). With treatment, the eventual family size of women with PMOS does not seem different to those without. The first-line medical treatment for infertility in women with PMOS is letrozole (Femara) to induce ovulation. This is, in general, more effective than clomiphene citrate to improve both pregnancy rates and live births. Other medications that can be used to treat infertility, listed from most to least effective, are metformin + clomiphene citrate, clomiphene citrate alone, and metformin alone. Women may be more likely to experience gastrointestinal side effects with metformin. Gonadotrophin therapy may be effective too, but requires monitoring and increases the risks of multiple pregnancies. When medication and lifestyle interventions are ineffective, infertility can be treated with a laparoscopic procedure called "ovarian drilling", which involves puncture of 4–10 small follicles with electrocautery, laser, or biopsy needles.

Pfizer opened a pilot plant with a 7,600-litre (2,000 US gal) fermentor in August 1943 and Ratajak delivered the first penicillin liquor from it on 27 August. The one tank was soon producing half the company's output. Smith then decided to construct a full-scale production plant. The nearby Rubel Ice plant was acquired on 20 September 1943 and converted into the first deep-submergence production plant, with fourteen 130,000-litre (34,000 US gal) tanks. The work was carried out in five months under the leadership of John E. McKeen and Edward J. Goett, and the plant opened on 1 March 1944.

== Historical background == Before 1932, British grocery stores operated as counter service; however, that year David Greig opened the first self-service grocery store in the UK at Turnpike Lane, Hornsey, but the store, although a success, was closed down after eight months of the experiment. The first permanent self-service grocery store in the United Kingdom was opened 12 January 1948 in Manor Park, London by the Co-op, with Tesco opening its first self-service grocery store and Marks & Spencer starting a trial of self-service in the same year. Sainsbury’s opened its first self-service branch in Croydon in 1950. By 1951, the Co-op had 604 self-service stores. In the same year, Express Dairies opened Britain's first supermarket under the Premier Supermarket brand in Streatham, South London, while the first Fine Fare was opened as a single supermarket later that year, as an offshoot of the Welwyn Department Store. Waitrose opened its first supermarket in Streatham during 1955, although its first self service store had opened at its subsidiary Schofield & Martin in 1951. Tesco, though, did not open its first supermarket until 1956 in Maldon, Essex, while Morrisons was not until 1961, and Asda was not until 1963. By 1959, multiple grocery retailers accounted for only 10% of grocery outlets and 25% of the British market; however, by a decade later the expansion of supermarkets had seen them take 41% of all grocery turnover. The growth of the supermarket is also shown in store numbers, with Britain having only 175 supermarkets in 1958, but this had expanded to 2,803 by 1967.

Sources: en.wikipedia.org

Background from the literature

== Career == An outstanding junior excluding one occasion where he was tagged out of the game by Martin Davis (now West Coast Eagles Property manager), Jetta was twice named in the Under 18 All-Australian Team as well as being adjudged the joint winner of the Kevin Sheehan Medal, awarded to the Best Player in Division 1 at the Under 16 National Championships. He was also a graduate of the AIS-AFL Academy in 2005. The speedy forward was drafted by the Bombers with the priority selection (18th overall) in the 2006 AFL draft from South Fremantle. He was drafted as a player renowned for outstanding pace, good foot skill and terrific vision on the ground. He made his AFL debut in the opening round of the 2007 season, along with another of the club's 2006 recruits, Alwyn Davey. Jetta went on to play the following 3 matches before being sidelined by a groin complaint. Despite returning to play with Essendon's VFL affiliate, the Bendigo Bombers, this injury ultimately ended his 2007 season. The 2008 pre-season, saw Jetta return to the club in excellent condition. He equaled the then club record for the 20m sprint with a time of 2.75 seconds, and his skin folds were the lowest they had been. His strong performances in the NAB Cup reflected that increase in fitness. As a result of that good form, Jetta earned selection in Essendon's Round 1 encounter with North Melbourne in which he gathered 13 possessions and showcased his terrific tackling. His good start to the season was interrupted by a hamstring injury sustained in Essendon's round 3 clash with Carlton.

Propofol is highly protein-bound in vivo and is metabolized by conjugation in the liver. The half-life of elimination of propofol has been estimated to be between 2 and 24 hours. However, its duration of clinical effect is much shorter because propofol is rapidly distributed into peripheral tissues. When used for IV sedation, a single dose of propofol typically wears off within minutes. Onset is rapid, in as little as 15–30 seconds. Propofol's versatility allows it to be used for short or prolonged sedation, and general anesthesia; and unlike opioid medications, its use is not associated with nausea. These characteristics of rapid onset and recovery along with its amnestic effects have led to its widespread use for sedation and anesthesia.

Pyrimidines are six-membered heterocyclic with nitrogen atoms in position 1 and 3. Purines are bicyclic, consisting of a pyrimidine fused to an imidazole ring. Artificial nucleotides (Unnatural Base Pairs (UBPs) named d5SICS UBP and dNaM UBP) have been inserted into bacterial DNA but these genes did not template mRNA or induce protein synthesis. The artificial nucleotides featured two fused aromatic rings which formed a (d5SICS–dNaM) complex mimicking the natural (dG–dC) base pair.

Oxymorphone, sold under the brand names Numorphan and Opana among others, is a highly potent opioid analgesic indicated for treatment of severe pain. Pain relief after injection begins after about 5–10 minutes; after oral administration it begins after about 30 minutes and lasts about 3–4 hours for immediate-release tablets and 12 hours for extended-release tablets. The elimination half-life of oxymorphone is much faster intravenously, and as such, the drug is most commonly used orally. Like oxycodone, which metabolizes to oxymorphone, oxymorphone has a high abuse potential. Oxymorphone was developed in Germany in 1914. It was patented in 1955 and approved for medical use in 1959. In June 2017 the FDA asked Endo Pharmaceuticals to remove its product from the US market. This was in part due to the opioid epidemic in the US, and the fact that a 2012 reformulation failed to stop illicit injection of the drug. Endo responded by voluntarily removing Opana ER from the market a month later. Generic versions of extended-release oxymorphone, such as those manufactured by Amneal Pharmaceuticals, are still available in the US.

Loncastuximab tesirine, sold under the brand name Zynlonta, is a monoclonal antibody conjugate medication used to treat large B-cell lymphoma and high-grade B-cell lymphoma. It is an antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19. The most common side effects include increased levels of gamma-glutamyltransferase (GGT, a liver enzyme), neutropenia (low levels of neutrophils, a type of white blood cell), tiredness, anemia (low levels of red blood cells), thrombocytopenia (low levels of blood platelets), nausea (feeling sick), peripheral edema (swelling due to fluid retention, especially of the ankles and feet) and rash. Loncastuximab tesirine was approved for medical use in the United States in April 2021, and in the European Union in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Sources: en.wikipedia.org

Frequently asked questions

How should AOD-9604 be stored?

Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.

What methods confirm AOD-9604 identity?

Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.

Why can purity vary between suppliers?

Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.

What is AOD9604 derived from?

AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.

Network